Chronic lymphocytic leukemia (CLL)

Dr. Jeff Sharman of Willamette Valley Cancer Institute and Research Center and Nichole Fisher, RN, BSN, discuss recent research presented at the 2019 American Society of Hematology (ASH) Annual Meeting, the current treatment landscape for CLL, and the impact a diagnosis can have on a patient and their loved ones.

As director of research at Willamette Valley Cancer Institute and medical director of hematology research for The US Oncology Network, Dr. Jeff Sharman is well versed in the latest scientific breakthroughs across a diversity of cancers.He’s been instrumental in developing a number of important advances in treatment and is widely published within the current scientific literature, including several publications within the New England Journal of Medicine, Journal of Clinical Oncology, Blood and others. A strategic thinker, Dr. Sharman’s research has helped position WVCI to have access to a variety of exciting new areas of research, including immunotherapy, targeted therapy and personalized medicine. The lessons learned from hematologic malignancies often apply to many different cancers and Dr. Sharman enjoys seeing all cancer patients.“While developments in research provide new avenues for hope, what means the most tome is being with patients in their moment of greatest need. The relationships that develop are often intense but very rewarding.”Outside the clinic, Dr. Sharman spends his time with family, enjoying the outdoors and Ducks football.